BAX Baxter International
8-K Current Report
Filed: March 16, 2026
Health Care
Surgical & Medical Instruments & ApparatusBaxter International (BAX) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • CFO Joel Grade out effective March 16, 2026; transitions to advisory role through April 30, 2026 with involuntary-termination severance under Executive Severance Plan
- • Anita Zielinski, SVP & Chief Accounting Officer, named interim CFO while permanent search underway — dual-role adds execution risk during ongoing restructuring
Item 7.01 · Regulation FD Disclosure
- • Baxter filed a Reg FD disclosure (Item 7.01), meaning material non-public information is being simultaneously released to all investors
- • Filing explicitly structured as "not filed" under Exchange Act Section 18 — limits shareholder litigation liability for the disclosed content
Other Baxter International 8-K Filings
Get deeper insights on Baxter International
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.